Drugs /

amg 337

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 337 selectively binds to c-Met, thereby disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.

Clinical Trials

View Clinical Trials for amg 337

Amg 337 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating amg 337, 2 are phase 2 (1 open).

EWSR1-ATF1 Fusion, MET Exon 14 Skipping, and MET Overexpression are the most frequent biomarker inclusion criteria for amg 337 clinical trials.

Clear cell sarcoma of soft tissue and malignant solid tumor are the most common diseases being investigated in amg 337 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Amg 337
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Amg 337
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating amg 337 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
c-met inhibitor amg 337, amg337
Drug Target(s) [2]:
MET
NCIT ID [1]:
C95203

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.